Also found in: Dictionary, Wikipedia.
Related to Humatrope: Norditropin, Genotropin

somatropin, recombinant

Genotropin, Humatrope, Norditropin, Nutropin AQ, Nutropin AQ Pen, Nutropin Depot, Omnitrope, Saizen, Serostim, Tev-Tropin, Zomacton (UK), Zorbtive

Pharmacologic class: Posterior pituitary hormone

Therapeutic class: Growth hormone (GH)

Pregnancy risk category B (Genotropin, Saizen, Serostim), C

Pregnancy risk category B (Genotropin, Saizen, Serostim), C


Stimulates linear and skeletal growth, increases number and size of muscle cells, and influences internal organ size


Genotropin injection: 1.5 mg (about 4 international units/vial), 5.8 mg (about 15 international units/vial), 13.8 mg (about 41.4 international units/vial)

Humatrope injection: 2 mg (about 6 international units/vial), 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial), 12 mg (about 36 international units/vial), 24 mg (about 72 international units/vial)

Norditropin injection: 4 mg (12 international units/vial), 8 mg (24 international units/vial)

Norditropin injection cartridge: 5 mg/1.5 ml, 10 mg/1.5 ml, 15 mg/1.5 ml

Nutropin AQ injection: 10 mg

Nutropin AQ Pen injection cartridge: 10 mg

Nutropin Depot: 13.5-mg, 18-mg, and 22.5-mg single-use vials; 13.5-mg, 18-mg, and 22.5-mg kits

Nutropin injection: 5 mg (about 15 international units/vial), 10 mg (about 30 international units/vial)

Saizem injection: 5 g (about 15 international units/vial)

Serostim injection: 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial)

Tev-Tropin injection: 5 mg

Zorbtive injection: 8.8 mg in 10-ml vial

Indications and dosages

Growth failure in children with inadequate endogenous GH

Children: 0.16 to 0.24 mg/kg (Genotropin) subcutaneously q week in six or seven divided doses. Or 0.18 mg/kg/week (Humatrope) subcutaneously or I.M., divided equally and given on three alternate days six times weekly (or daily, if epiphyseal closure hasn't occurred). Or 0.024 to 0.034 mg/kg (Norditropin) subcutaneously six or seven times each week using NordiPen injection pen. Or 0.3 mg/kg/week (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously in equally divided daily doses. Or 0.06 mg/kg (Saizen) subcutaneously or I.M. three times weekly.

Endogenous GH replacement in adults with GH deficiency

Adults: 0.04 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses. Or 0.006 mg/kg/day (Humatrope) subcutaneously. Or initially, no more than 0.006 mg/kg/day (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously; may increase to a maximum of 0.025 mg/kg daily in patients younger than age 35 or 0.0125 mg/kg/day in patients ages 35 and older. Or 0.005 mg/kg/day (Saizen) subcutaneously; may increase to a maximum of 0.01 mg/kg/day after 4 weeks, depending on patient tolerance.

Short stature related to Turner's syndrome

Children: 0.375 mg/kg/week (Humatrope) subcutaneously, divided into equal doses given on 3 alternate days or daily. Or up to 0.375 mg/kg/week (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into equal doses given three or seven times weekly.

Idiopathic short stature (non-GH-deficient) in children whose epiphyses haven't closed

Children: Up to 0.37 mg/kg (Humatrope) subcutaneously q week. Divide dosage and give in equal doses six or seven times weekly.

Growth failure in children with Prader-Willi syndrome

Children: 0.24 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

Infants born small for gestational age

Children: 0.48 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

AIDS wasting or cachexia

Adults and children weighing more than 55 kg (121 lb): 6 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 45 to 55 kg (99 to 121 lb): 5 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 35 to 45 kg (77 to 99 lb): 4 mg (Serostim) subcutaneously at bedtime

Adults and children weighing less than 35 kg (77 lb): 0.1 mg/kg/day (Serostim) subcutaneously at bedtime

Growth failure due to chronic renal insufficiency (up to time of kidney transplantation)

Children: Up to 0.35 mg/kg/weekly (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into daily doses

Short bowel syndrome in patients receiving specialized nutritional support

Adults: 0.1 mg/kg/day subcutaneously (Zorbtive), to a maximum of 8 mg/day for no more than 4 weeks


• Hypersensitivity to drug, benzyl alcohol, glycerin, or metacresol (with some diluents)
• Active neoplasia
• Acute, critical illness after open-heart surgery, acute respiratory failure, or multiple trauma
• Children with closed epiphyses
• Neonates (Zorbtive)


Use cautiously in:
• hypothyroidism
• diabetes mellitus.


• Reconstitute by injecting supplied diluent through rubber top of vial and aiming liquid stream at side of vial. Swirl vial gently to mix; don't shake.
• Inspect reconstituted solution. Don't use if it has visible particles or is cloudy.
• Keep diluted drug refrigerated; use within 14 days.
• When using prefilled cartridges, follow manufacturer's instructions carefully.
• Know that patients receiving Zorbtive for short bowel syndrome may receive specialized nutritional support as needed.

Adverse reactions

CNS: headache, weakness

CV: mild and transient edema

GU: hypercalciuria

Hematologic: leukemia

Metabolic: fluid retention, mild hyperglycemia, hypothyroidism, ketosis

Musculoskeletal: localized muscle pain, tissue swelling, joint pain

Skin: rash, urticaria

Other: pain, inflammation at injection site


Drug-drug.Androgens, thyroid hormone: epiphyseal closure

Corticotrophin, corticosteroids: inhibited growth response (with long-term use)

Drug-diagnostic tests.Alkaline phosphatase, glucose, inorganic phosphorus, parathyroid hormone: increased levels

Patient monitoring

• Monitor patient's height, X-rays, blood chemistry results, blood glucose level, and thyroid function studies.

Watch for signs and symptoms of leukemia.

Patient teaching

• Advise patient and parents that regular check-ups and blood tests are needed to detect adverse reactions.
• Teach parents how to reconstitute and administer drug. Stress importance of following manufacturer's instructions carefully when using prefilled cartridges.
• Teach parents about proper handling and disposal of syringes, needles, and cartridges.
• As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


A trademark for a preparation of recombinant human growth hormone (somatropin).


a trademark for a brand of human synthetic growth hormone produced with recombinant deoxyribonucleic acid techniques. It is a polypeptide hormone with 191 amino acids in the same sequence as somatotropin, the human growth hormone produced by the pituitary gland.


Injectable rDNA somatropin Endocrinology A growth hormone for adult somatropin deficiency and short stature in girls with Turner syndrome. See Turner syndrome.


A brand name for SOMATOTROPIN.
References in periodicals archive ?
Genotropin, Humatrope, Nutropin, Saizen, and Others MarketsIndependently Analyzed with Annual Sales Figures in US$
Now Humatrope is indicated for patients with severe adult growth hormone deficiency.
The company invested pounds 50m last year extending manufacturing capacity for Humatrope.
The biosimilars used to treat GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin.
The money will fund expansion and modernisation of its Humatrope production facilities, leading to 50 building jobs and 25 new positions.
Such biologics include Cerezyme (alglucerase), Humulin (human insulin), Intron A (interferon alpha-2b), Avonex (interferon beta-1a), Humatrope (somatropin), Epogen (epoetin alfa) and Neupogen (filgrastim).
COMPETITION II-18 MNC Manufacturers Dominate hGH Market, New Entrants to Intensify Competition II-18 Table 4: Worldwide Human Growth Hormone Drugs Market by Leading Players (2014): Percentage Market Share Breakdown of Sales Revenues for Eli Lilly, Novo Nordisk, Merck Serono, Pfizer, Roche/Genentech, and Others (includes corresponding Graph/Chart) II-19 Norditropin II-19 Genotropin II-19 Humatrope II-20 Saizen II-20 Omnitrope - the Somatropin Biosimilar II-20 Somatropin Biopartners II-21 Review of Select hGH Products in Pipeline II-21 OPKO Biologics/ Prolor Biotech's hGH-CTP II-21 Versartis VRS-317 II-22 Ambrx ARX201 II-22 HanAll's Vitatropin II-22
The Speke operation is Lilly's worldwide supplier of Humatrope,abiotech product used to treat growth hormone deficiency.
LillyMedicareAnswers[TM] Will Provide Zyprexa, Forteo and Humatrope to Low-Income Seniors Who Are Experiencing Gaps in Coverage; Program to Launch in January 2007
Rest of the World Human Growth Hormone (Somatropin) -- Genotropin -- Humatrope -- Norditropin -- Nutropin -- Saizen -- Biosimilar Somatropin?
LillyMedicareAnswersao will provide Zyprexa, Forteo and Humatrope to low-income
19 Summary sales data 20 Company specific sales data 23 Genotropin 23 Humatrope 23 Norditropin/other Novo Nordisk HGH products 24 Nutropin 24 Saizen/Serostim 25 Bio-Tropin/Tev-Tropin 26 Current biosimilar activity 27 USA 27 European Union 27 Rest of the world 27 G-CSF 29 What is it?